A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956)
(2005) Lung Cancer — Vol. 50, n° 1, p. 91-96 (2005)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 113.07 KB
Details
- Authors
- et. al.
- Abstract
- Purpose: The incidence of bronchioloalveolar carcinoma (BAC) has risen steadily over the last decades along with the increasing frequency of adenocarcinomas. BAC is relatively resistant to commonly used chemotherapy regimens. A phase II study with single agent paclitaxel in patients with stages IIIB, IV or recurrent BAC was performed. Experimental design: Patients with BAC with at least one target bidimensionally measurable lesion staged as unresectable stages IIIB, IV or recurrent disease, not previously irradiated; ECOG performance status 0–2; life expectancy greater than 3 months; age range between 18 and 75, received paclitaxel at a dose of 200 mg/m2 i.v. as 3 h continuous infusion on day 1 every 21 days. Treatment was continued until progression or up to a maximum of six cycles. Results: Nineteen patients were eligible. Median number of cycles was 3 (range 0–6); 35% of patients received the planned six cycles of chemotherapy. One patient died of unrelated cause before the start of treatment. Both hematological and non-hematological toxicities were generally mild. Only one partial response (PR) was observed among the 18 eligible patients who started protocol treatment, with a response rate of 5.6% (95% CI: 0.1–27.3%). After an independent review, two PR were confirmed, for a response rate of 11.1% (95% CI: 1.4–34.7%); nine patients had stable disease (50.0%), three patients had progressive disease (11.1%) and four patients were not assessable (22.2%). Median survival was 8.6 months (95% CI: 5.8–14.5) and 1-year survival was 35.0% (95% CI: 14.1–55.8). Median progression free survival for all patients was 2.2 months (95% CI: 1.5–6.0). The study was terminated due to the low response rate. Conclusions: Paclitaxel
- Affiliations
Citations
Scagliotti, G. V., Smit, E., Bosquee, L., O’Brien, M., Ardizzoni, A., Zatloukaf, P., Eberhardt, W., Smid-Geirnaerdt, M., de Bruin, H. G., Dussenne, S., Legrand, C., Giaccone, G., & et al. (2005). A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer, 50(1), 91-96. https://doi.org/10.1016/j.lungcan.2005.05.012 (Original work published 2005)